David leads company creation efforts for the Frazier Life Sciences team, bringing over 15 years of experience forming and building therapeutics-focused companies.
David joined Frazier Healthcare Partners in 2014 as a Venture Partner and is focused on new company creation. In this capacity, he co-founded Outpost Medicine, Passage Bio, Phathom Pharmaceuticals, Recida Therapeutics, and Scout Bio. David was CEO of Outpost and Scout and currently serves as CEO of Phathom, Executive Chairman of Recida and as a board member of Outpost.
Prior to joining Frazier, David co-founded Incline Therapeutics in 2010 and served as its President and Chief Operating Officer until its sale to The Medicines Company in 2013 for up to $390 million. He also co-founded Cadence Pharmaceuticals in 2004 and served as its Senior Vice President, Corporate Development and Strategy. Cadence completed its IPO in 2006, received FDA approval for OFIRMEV (acetaminophen injection) in 2010, and was acquired by Mallinckrodt in 2013 for $1.3 billion. Both Incline and Cadence are exited portfolio companies of Frazier.
From 2000-2004, David was a Venture Partner at Windamere Venture Partners, where he co-founded companies such as Avera Pharmaceuticals, Kanisa Pharmaceuticals, Somaxon Pharmaceuticals (acquired by Pernix Therapeutics), and Verus Pharmaceuticals (acquired by AstraZeneca and Shionogi/Sciele). Previously, he worked at Neurocrine Biosciences, EFO Holdings, and Kaiser Associates.
David holds a B.S. from Georgetown University and an M.B.A. from Stanford University.
Georgetown University (B.S.)
Stanford University (M.B.A.)